Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 147

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 147
---
 of Reed Smith's Philadelphia office (2003 to 2014), where he was a member of the firm's global executive committee.

Mr. Raju also sits on a number of civic boards, including the Philadelphia Museum of Art, the Greater Philadelphia Chamber of Commerce, the Zicklin Center at Wharton, the President's Council at Temple University and the Research Council at Penn Medicine.

Mr. Raju received his Bachelor of Arts and Juris Doctor degrees from Temple University.

Patrick J. Mahaffy, Director

Patrick J. Mahaffy has served as a member of our board of directors since August 2025.

Mr. Mahaffy is a biopharmaceutical executive with a track record of serial value creation in the field of oncology-focused drug development and commercialization in the US and Europe. He has successfully led multiple companies as President, CEO and Board Chair and served on the boards of several high-growth biotechnology companies and he brings strategic vision and insightful perspective on commercial development, marketing, portfolio strategy and operational and management expertise specific to novel oncology therapeutics, as well as targeted radiotherapeutics, an exciting area of oncology drug development. Most recently, Mr. Mahaffy served as the Chairman of the Board of Antev from March 2024 until August 2025. Previously, Mr. Mahaffy was the President and CEO of Clovis Oncology, Inc. ("Clovis") (Nasdaq: CLVS), a company he co-founded in 2009. Under his leadership Clovis developed, gained approvals for and marketed Rubraca, a drug for ovarian and prostate cancer in the US and Europe, and commenced early-stage clinical development of a targeted radionuclide therapy.

Prior to Clovis, Mr. Mahaffy served as the President and CEO of Pharmion Corporation, a global drug development and commercialization company focused on hematological and solid tumor cancers, from 2000 to 2008 when it was acquired by Celgene (now Bristol Myers Squibb) for $2.9 billion. Its primary drug, Vidaza, remains today the standard of care for the treatment of myelodysplastic syndrome and acute myeloid leukemia.

Mr. Mahaffy's first role as CEO was at Nexstar Pharmaceuticals, focused on the discovery, development, manufacture and commercialization of products to treat serious and life-threatening illnesses including cancer. which he led from 1992 to 1998, prior to its 1999 acquisition by Gile